Drug Trial Radar · NCT07229599
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 9, 2025
Primary completion
May 2029
Study completion May 2030
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.
Conditions
- Advanced Lung Cancer
Interventions
MHB036C for InjectionDrug
IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
MHB039A for InjectionDrug
IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
FurmonertinibDrug
Oral administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
CarboplatinDrug
IV administration; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Dose-Escalation Stage): Maximum tolerated dose (MTD) for MHB036C and other anti-tumor treatment combination therapyTime frame: Up to day 21 from the first dose for Q3W administration.
- (Dose-Escalation Stage): Incidence and severity of adverse events (AEs)Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years.
- (Dose-Expansion Stage): Objective tumor response (ORR) determined by investigators according to RECIST v1.1Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.